Latest news with #Angèle
Fashion Network
30-07-2025
- Business
- Fashion Network
From Estée Lauder to Lancel: Paola Falchi steps in as MD
A new chapter begins at Lancel as Paola Falchi is appointed to lead the historic French leather goods house. Owned by Italy's Piquadro Group since 2018, the brand — originally founded in 1876 by Angèle and Alphonse Lancel — is now under Falchi's direction. She succeeds Francesco Pesci, who had overseen the Paris-based label since January 2023. The brand's new leader, who began her career in finance departments in the pharmaceutical industry, expanded her expertise with an executive MBA at HEC in 2018. With experience as director of corporate finance at Estée Lauder and director of operations, finance, and strategy at Issey Miyake Europe between 2020 and late 2024, Paola Falchi now joins a company in renewed health. For the 2024–2025 financial year, the company reported sales of €68.8 million, up 6.5% from the previous year. 'Lancel is a company with a unique heritage and strong growth potential. The challenge is to extend this history by building sustainable growth, based on agility, innovation, and the highest standards of customer service. I am delighted to contribute, alongside the Piquadro Group, to the realisation of this ambition,' said the CEO in the brand's press release.
Fashion Network
30-07-2025
- Business
- Fashion Network
From Estée Lauder to Lancel: Paola Falchi steps in as MD
A new chapter begins at Lancel as Paola Falchi is appointed to lead the historic French leather goods house. Owned by Italy's Piquadro Group since 2018, the brand — originally founded in 1876 by Angèle and Alphonse Lancel — is now under Falchi's direction. She succeeds Francesco Pesci, who had overseen the Paris-based label since January 2023. The brand's new leader, who began her career in finance departments in the pharmaceutical industry, expanded her expertise with an executive MBA at HEC in 2018. With experience as director of corporate finance at Estée Lauder and director of operations, finance, and strategy at Issey Miyake Europe between 2020 and late 2024, Paola Falchi now joins a company in renewed health. For the 2024–2025 financial year, the company reported sales of €68.8 million, up 6.5% from the previous year. 'Lancel is a company with a unique heritage and strong growth potential. The challenge is to extend this history by building sustainable growth, based on agility, innovation, and the highest standards of customer service. I am delighted to contribute, alongside the Piquadro Group, to the realization of this ambition,' said the CEO in the brand's press release. Lancel operates a network of around 15 boutiques and 40 department store corners in France. It also has a dozen standalone stores abroad, notably in Southeast Asia.
Fashion Network
30-07-2025
- Business
- Fashion Network
From Estée Lauder to Lancel: Paola Falchi steps in as MD
A new chapter begins at Lancel as Paola Falchi is appointed to lead the historic French leather goods house. Owned by Italy's Piquadro Group since 2018, the brand — originally founded in 1876 by Angèle and Alphonse Lancel — is now under Falchi's direction. She succeeds Francesco Pesci, who had overseen the Paris-based label since January 2023. The brand's new leader, who began her career in finance departments in the pharmaceutical industry, expanded her expertise with an executive MBA at HEC in 2018. With experience as director of corporate finance at Estée Lauder and director of operations, finance, and strategy at Issey Miyake Europe between 2020 and late 2024, Paola Falchi now joins a company in renewed health. For the 2024–2025 financial year, the company reported sales of €68.8 million, up 6.5% from the previous year. 'Lancel is a company with a unique heritage and strong growth potential. The challenge is to extend this history by building sustainable growth, based on agility, innovation, and the highest standards of customer service. I am delighted to contribute, alongside the Piquadro Group, to the realization of this ambition,' said the CEO in the brand's press release. Lancel operates a network of around 15 boutiques and 40 department store corners in France. It also has a dozen standalone stores abroad, notably in Southeast Asia.
Vogue Arabia
06-06-2025
- Business
- Vogue Arabia
Angèle Partners with Chanel Beauty for its New Scent
Pioneering a form of urban pop that's fresh and fluid while championing feminist causes close to her heart, singer and songwriter Angèle is a rising French and Belgian pop music star. She topped charts for nine weeks in a row with her 2018 track, Tout Oublier, collaborated with Dua Lipa on Fever in 2020 and made her musical film debut in Anette in 2020. In 2023, she won the award for the most streamed female album during the annual French music awards and last year, she performed at the Paris Olympics closing ceremony. Not only is she the face of Chanel Beauty's latest launch – Chance Eau Splendide – but she also composed a new song, A Little More, for the campaign. The new fragrance, with its revitalising fruity-floral scent and refreshing lilac tint, was inspired by Gabrielle Chanel's reverence for luck – which, more than just good fortune, is an everlasting mindset to embody. This content can also be viewed on the site it originates from. How do you manifest luck and good fortune? I've been very lucky in my life, and being here today is proof of that! I believe I also have the good fortune of being an optimist. I like to move toward joy. We must never forget that one of the solutions to anxiety is joy. Joy is very powerful – it's a real mantra for me. As long as we can, as long as we have the opportunity, we must cherish and maintain our joy, which opens the door to even more luck and optimism. If it doesn't work this time, it will tomorrow. There is no luck without audacity. What's the biggest risk you've ever taken? I took my two managers by the hand, and we went to Paris to play our demos. It was a real gamble! I suddenly found myself face to face with people from the music industry. I was afraid they wouldn't understand the direction I wanted to go in. I wanted to remain independent, to write and produce my songs under my own label and publishing company. It was a big risk. At the time, the path to independence, which today seems obvious to me, was difficult to take. And I'm still grateful for that audacity – that desire to dive headfirst, that I had at that age. Wearing perfume is like wearing invisible armour. What does this gesture mean to you? For me, wearing perfume is a way of giving yourself momentum. Strength. When I put on perfume, I instinctively set myself in motion. My perfume is the final touch before leaving the house and opening myself up to the world, to others. It gives me confidence. After getting dressed and putting on makeup, I put on my perfume, and I feel complete. The new fragrance is inspired by the kind of luck you seize. Do you remember the day you encountered a life-changing opportunity? When I was 20, this incredible woman I'd known since childhood contacted me and said she'd seen my videos on Instagram. She asked me, "What if we worked together?" At that point, I'd never dared to consider a career as a musician. It seemed like a totally insurmountable challenge. Nevertheless, I agreed to discuss it. And in the end, it wasn't just a discussion. When I got home, I immediately got to work, installed music production software which I still use today, and created my first songs, productions and lyrics. There are encounters that change your life; people you meet along the way who transform your journey.
Business Wire
03-06-2025
- Business
- Business Wire
Ability Biotherapeutics Welcomes Angèle Maki, PhD to its Board of Directors
MONTREAL--(BUSINESS WIRE)--Ability Biotherapeutics, a biotechnology leader focused on developing next-generation antibody therapies, is pleased to announce the appointment of Angèle Maki, PhD to its Board of Directors. Dr. Maki brings over 20 years of experience in the biopharmaceutical industry, with a distinguished track record of leadership in business development and strategic partnerships across both emerging biotech ventures and global pharmaceutical companies. She currently serves as Chief Business Officer at Callio Therapeutics, a company realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. Over the course of her career, Dr. Maki has held senior roles at leading organizations including Medarex (acquired by Bristol Myers Squibb), Bristol Myers Squibb, Genentech, Merck & Co., Eli Lilly, ReCode Therapeutics, and Hummingbird Bioscience which spun out Callio Therapeutics. She has led and executed a broad spectrum of transactions across modalities and therapeutic areas—from early research collaborations to therapeutic licensing agreements and acquisitions—and played a key role in the venture strategy while at Eli Lilly. 'We are thrilled to welcome Angèle to our Board of Directors at this pivotal stage in Ability's growth,' said Giles Day, Chief Executive Officer of Ability Biotherapeutics. 'Her deep experience in business development, licensing, and strategic partnerships across both biotech and pharma will be invaluable as we advance our lead antibody programs toward preclinical development and prepare for our first human clinical trials. As Ability continues to build momentum, Angèle's insights and leadership will help guide us through the critical decisions that lie ahead.' In addition to her corporate roles, Dr. Maki is a passionate advocate for innovation and entrepreneurship. She currently serves as Board Chair of Canadian Entrepreneurs in Life Sciences (CELS), a non-profit organization supporting emerging leaders in the sector. Dr. Maki earned her Ph.D. in Biological Chemistry from Stanford University and holds a in Chemistry from the University of Winnipeg. 'I'm truly delighted to join the Board of Directors at Ability Biotherapeutics,' said Dr. Maki. 'Ability's bold mission to revolutionize targeted antibody therapies for cancer and autoimmune diseases, combined with the team's scientific excellence and innovative spirit, makes it an incredibly exciting company to support. I look forward to contributing to its continued growth as it advances toward clinical development and strives to improve patient outcomes.' About Ability Biotherapeutics Ability Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. To learn more, visit their LinkedIn page, or contact them at partnering@
